Furthermore we suggest that a phase of priming with T is necessary to obtain the high behavioral responsiveness to a challenge.
This was greatest for the disease activity domain, which was divided into five subdomains (clinical measures, physiological tests of lung function, global measures, bronchial responsiveness to a challenge agent or exercise and markers of inflammation), each of which included outcomes measured in different ways.
Above all, our data support the hypothesis that the response to a mini-fluid challenge can predict responsiveness to a larger challenge.
Our findings demonstrated that these patients showed reduced responsiveness to a lipopolysaccharide challenge (which is called endotoxin tolerance) but their monocytes were not paralysed.
It is known that both ventilation and deep inspiration can transiently decrease the airway responsiveness to an agonist challenge [1], [2], [3], [31], [32], [33], [34], [35], so it is possible that the decreased response to the aerosol challenge resulted from the delivery procedure.
Endotoxin tolerance is defined as a reduced responsiveness to a lipopolysaccharide (LPS) challenge following a first encounter with endotoxin.
Alternatively sufficient is having two of the features, with one of first three asymmetrical (Responsiveness to a dopaminergic drug challenge was not a requirement).
Indeed, in the last ten years a major challenge to predict the responsiveness to a given therapeutic plan has been the identification of tumor specific signatures, with the aim to reduce the frequency of unwanted side effects on oncologic patients not responding to therapy.
A trend was seen in the regression analysis between a small cortisol response to buspirone challenge and increased pain, but the cortisol responsiveness to serotonergic challenge only explained a minor and nonsignificant part of variance in pain.
The study measured only changes in airways responsiveness to AMP challenge, which is a useful marker of corticosteroid anti-inflammatory activity but also of the effects of the LABA component [ 16, 17].
Finally, for control of low-grade metabolic inflammation, one could select a combination of markers including responsiveness to inflammatory challenge, CRP and pro- and anti-inflammatory mediators.
